VIDEO: Multiple myeloma highlights from ASH 2023
Click Here to Manage Email Alerts
In this video, Samer Al Hadidi, MD, MS (CRDSA), FACP, of Winthrop P. Rockefeller Cancer Institute at University of Arkansas for Medical Sciences, discussed multiple myeloma presentations from ASH Annual Meeting and Exposition.
He highlighted a plenary session and late-breaking abstract that asked similar questions but focused on different therapies for multiple myeloma.
“The excitement in ASH came from that fact that both trials are phase 3 trials, which are — as we all know — providing better evidence when it comes to the actual efficacy of those drugs,” Al Hadidi told Healio.
Also important at ASH this year were trials investigating how to improve outcomes among hard-to-treat patients, he said.
“As many know that the improvement in multiple myeloma outcomes were centered around standard-risk patients,” Al Hadidi said. “Unfortunately, with high-risk patients we did not do as well as we are doing currently with standard risk, and the goal for future therapies was to look into how we can do better.”
Finally, he noted presentations from the meeting that focused on advancing diagnostic methods.
“We always want to do better when it comes to diagnostic procedures, especially in multiple myeloma,” Al Hadidi said.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts